InspireMD (NYSEAMERICAN:NSPR)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Wednesday.

NSPR opened at $0.15 on Wednesday. InspireMD has a fifty-two week low of $0.13 and a fifty-two week high of $3.19.

InspireMD (NYSEAMERICAN:NSPR) last released its quarterly earnings results on Tuesday, February 19th. The medical equipment provider reported ($0.05) earnings per share for the quarter. The company had revenue of $0.82 million for the quarter.

An institutional investor recently bought a new position in InspireMD stock. Barclays PLC acquired a new position in shares of InspireMD Inc (NYSEAMERICAN:NSPR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 162,797 shares of the medical equipment provider’s stock, valued at approximately $26,000. Barclays PLC owned about 0.39% of InspireMD as of its most recent filing with the Securities and Exchange Commission (SEC).

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Read More: How does new data get added to a blockchain?

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with's FREE daily email newsletter.